Answers are grounded in this paper and cite their sources.
Simvastatin (SMS) has profound lipid-independent "pleiotropic" effects that benefit heart failure (HF), but its poor solubility and bioavailability limit its efficacy. This study developed nasal simvastatin-loaded transbilosomes (SLT) to improve drug solubility and bioavailability and mitigate HF. To develop an optimal SLT formulation, the Box-Behnken design was employed. The effectiveness of the nasal SLT was evaluated in vivo using rat models of HF induced by either doxorubicin or ischemia/reperfusion. Relative to free SMS, the optimal SLT achieved a release increase of 3.81-fold, increased bioavailability by 6.35-fold, enhanced permeation by 7.46-fold, and increased the cardiac accumulation by 1.96-fold. Compared to the oral SMS group, the nasal SLT group exhibited significantly lower levels of triglycerides, cholesterol, LDL, CK-MB, LDH, troponin I, NT-proBNP, NO, MDA, and heart rate, being 1.49-fold, 1.47-fold, 1.40-fold, 1.48-fold, 1.42-fold, 1.59-fold, 1.42-fold, 2.0-fold, 1.90-fold, and 1.99-fold lower, respectively. Conversely, HDL, GSH, SOD, ejection fraction, and fractional shortening increased by 1.5-fold, 1.95-fold, 1.48-fold, 1.48-fold, and 1.42-fold, respectively. Histopathology examination validated the efficacy of the nasal SLT formulation. While these findings represent nasal SLT as a promising insight in alleviating HF, future work is recommended to fully elucidate the distinct contribution of isolated vehicle and route controls.
No takes yet. Share an insight, caveat, or question.
Rofaiel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: